Regeneron (RGEN) Gets FDA Approval for EYLEA as Macular Edema Treatment

September 21, 2012 2:09 PM EDT Send to a Friend
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login